Psilocybin safety and medical screening
SAFETY
A growing clinical evidence base
30+ controlled academic studies of psilocybin-assisted approaches in adults
Imperial College LondonNEJM · Randomised controlled trial · Major depressive disorder · 2021View study
Johns Hopkins School of MedicineJAMA Psychiatry · Randomised clinical trial · Major depressive disorder · 2021View study
University of ZurichEClinicalMedicine · Double-blind placebo-controlled trial · Major depressive disorder · 2022View study
Where access already exists
A number of countries have created some route to supervised psilocybin-assisted work. The models differ widely in who may take part and on what basis, and none of them describes the ONCE pathway.
- The NetherlandsPsilocybin-containing sclerotia are reported as not listed under the Opium Act.
- AustraliaSince 2023, authorised psychiatrists may prescribe psilocybin for treatment-resistant depression under the national medicines regulator.
- SwitzerlandSince 2014, individual exemptions granted case by case to authorised psychiatrists for severe conditions.
- CanadaAdded to the Special Access Programme in 2022 for serious, life-threatening illness.
- Oregon & Colorado, USState-regulated supervised service centres, outside the medical route and without a diagnosis requirement.
- CzechiaLegislation reported as adopted in 2025 to permit medical use from 2026.
Start with clarity.
Begin with a confidential preliminary assessment. It helps you organise what you are experiencing and identify questions that may need professional review.